143 related articles for article (PubMed ID: 28169232)
21. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
22. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
23. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
Kato N; Tanaka J; Sugita J; Toubai T; Miura Y; Ibata M; Syono Y; Ota S; Kondo T; Asaka M; Imamura M
Leukemia; 2007 Oct; 21(10):2103-8. PubMed ID: 17625602
[TBL] [Abstract][Full Text] [Related]
24. In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer.
Schrambach S; Ardizzone M; Leymarie V; Sibilia J; Bahram S
PLoS One; 2007 Jun; 2(6):e518. PubMed ID: 17565371
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
26. Matrix metallopeptidase 2 (MMP2) mediates MHC class I polypeptide-related sequence A (MICA) shedding in renal cell carcinoma.
Yang FQ; Liu M; Yang FP; Zhang XL; Yang B; Guo CC; Huang JH; Che JP; Yan Y; Zheng JH
Actas Urol Esp; 2014 Apr; 38(3):172-8. PubMed ID: 24461475
[TBL] [Abstract][Full Text] [Related]
27. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.
Schilling D; Kühnel A; Tetzlaff F; Konrad S; Multhoff G
Cancer Immunol Immunother; 2015 May; 64(5):599-608. PubMed ID: 25854583
[TBL] [Abstract][Full Text] [Related]
28. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
29. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
30. Exosomes and the MICA-NKG2D system in cancer.
Clayton A; Tabi Z
Blood Cells Mol Dis; 2005; 34(3):206-13. PubMed ID: 15885603
[TBL] [Abstract][Full Text] [Related]
31. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer.
Huang B; Sikorski R; Sampath P; Thorne SH
J Immunother; 2011 Apr; 34(3):289-96. PubMed ID: 21389869
[TBL] [Abstract][Full Text] [Related]
32. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
[TBL] [Abstract][Full Text] [Related]
33. Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4.
Zöller T; Wittenbrink M; Hoffmeister M; Steinle A
Front Immunol; 2018; 9():620. PubMed ID: 29651291
[TBL] [Abstract][Full Text] [Related]
34. Ethanol-dependent expression of the NKG2D ligands MICA/B in human cell lines and leukocytes.
Streltsova MA; Klinkova AV; Kuchukova AA; Kadin AY; Kanevskiy LM; Kovalenko EI
Biochem Cell Biol; 2017 Apr; 95(2):280-288. PubMed ID: 28177768
[TBL] [Abstract][Full Text] [Related]
35. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.
Salih HR; Goehlsdorf D; Steinle A
Hum Immunol; 2006 Mar; 67(3):188-95. PubMed ID: 16698441
[TBL] [Abstract][Full Text] [Related]
36. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
37. Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients.
Wang H; Yang D; Xu W; Wang Y; Ruan Z; Zhao T; Han J; Wu Y
Immunol Lett; 2008 Oct; 120(1-2):65-71. PubMed ID: 18672004
[TBL] [Abstract][Full Text] [Related]
38. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.
Holdenrieder S; Stieber P; Peterfi A; Nagel D; Steinle A; Salih HR
Cancer Immunol Immunother; 2006 Dec; 55(12):1584-9. PubMed ID: 16636811
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.
Xu X; Rao G; Gaffud MJ; Ding HG; Maki G; Klingemann HG; Groh V; Spies T; Caillat-Zucman S; Gattuso P; Plate J; Prinz RA
J Clin Endocrinol Metab; 2006 Jul; 91(7):2704-12. PubMed ID: 16621903
[TBL] [Abstract][Full Text] [Related]
40. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.
Kloess S; Huenecke S; Piechulek D; Esser R; Koch J; Brehm C; Soerensen J; Gardlowski T; Brinkmann A; Bader P; Passweg J; Klingebiel T; Schwabe D; Koehl U
Eur J Immunol; 2010 Nov; 40(11):3255-67. PubMed ID: 21061445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
